Name: Big Pharma, Big Greed: The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health (en Inglés)
Price: 23490.00 CLP
Availability: InStock
Author: Kirkpatrick, Sidney ; Mondics, Christopher ; Sheller, Stephen
ISBN: 9781947492257

portada Big Pharma, Big Greed: The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health (en Inglés)

Formato

Libro Físico

Autor

Editorial

Idioma

Inglés

N° páginas

154

Encuadernación

Tapa Blanda

Dimensiones

22.9 x 15.2 x 0.9 cm

Peso

0.24 kg.

ISBN13

9781947492257

Categorías

Derechos sobre la protección de consumidores y usuarios y consumo

Big Pharma, Big Greed: The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health (en Inglés)

Sidney Kirkpatrick (Autor) · Christopher Mondics (Autor) · Stephen Sheller (Autor) · Strong Arm Press · Tapa Blanda

Libro Nuevo

$ 23.490

$ 39.150

Ahorras: $ 15.660

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 18 de Junio y el Jueves 27 de Junio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Big Pharma, Big Greed: The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health (en Inglés)"

In "Big Pharma, Big Greed: The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health", Stephen Sheller tells a tale that is at once deeply personal but also with wide repercussions for the U.S. health care system and the hundreds of millions of Americans whose lives literally depend on it. In the book, Sheller not only recounts his major litigation battles but also makes sweeping proposals for industry reform. To restore regulatory credibility, Sheller proposes that responsibility for testing new medicines be taken away from the industry and given over to hospitals and other public entities partnering with government regulators. Pharmaceutical companies that betray the public trust would risk government- initiated dissolution. Harsh medicine to be sure, but Sheller believes entirely appropriate to the underlying malady.